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Summary
Objective: Intraarticular injections of sodium hyaluronate (Na-HA) appear effective in reducing subjective symptoms of osteoarthritis (OA) and
may also have protective effects on the cartilage matrix. The present study analyzed the suppressive effects of Na-HA on the release and
degradation of aggrecan and on levels of nitric oxide (NO) in the joint ﬂuid of patients with knee OA.
Design: Sixteen OA patients with knee joint effusion were treated by 5 weekly intraarticular injections of Na-HA. Prior to each Na-HA injection,
joint ﬂuid was collected to determine the levels of chondroitin 4-sulfate (C4S) and chondroitin 6-sulfate (C6S), intact aggrecan and NO.
Results: One week after the ﬁnal injection, the joint ﬂuid levels of C4S, C6S, and NO were signiﬁcantly decreased. In contrast, the joint ﬂuid
level of intact aggrecan was stable during the series of Na-HA injections. A trend was seen for a positive correlation (P!0:1) between the
clinical score and C4S or C6S joint ﬂuid levels, and for a negative correlation between the joint ﬂuid levels of intact aggrecan and C4S or C6S.
No signiﬁcant correlations were observed between joint ﬂuid levels of NO, the clinical score, and levels of C4S, C6S, and intact aggrecan.
Conclusion: The results of this study suggest that intraarticularly injected Na-HA is able to improve the clinical symptoms of OA partially based
on its ability to reduce the release and degradation of aggrecan and/or to enhance the synthesis of aggrecan in the joint tissues of the patients
with knee OA. While Na-HA also reduces the NO level in the joint ﬂuid of patients with knee OA, this effect may be independent from the other
effects of Na-HA.
 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is characterized by the progressive
erosion of articular cartilage and represents one of the most
prevalent diseases in older individuals. The extensive
extracellular matrix of hyaline cartilage contains a dense
network of composite collagen ﬁbrils composed mainly of
type II, together with type IX and XI collagens1. Contained
within this network are large proteoglycans; one of them,
aggrecan, has the ability to aggregate with hyaluronan
(HA)1. In adult human cartilage, aggrecan contains a rela-
tively large proportion of the glycosaminoglycans, chondroi-
tin sulfate (CS) and keratan sulfate (KS)2. It is well known
that the release and degradation of aggrecan is accelerated
with the progress of cartilage destruction in the joints of
patients with OA1. Therefore, the amount of aggrecan and/or
degree of degradation of aggrecan released into the joint
ﬂuid reﬂects, in part, the pathology of OA3e6.
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of catabolic biomolecular mediators, such as nitric oxide
(NO), contributes to the pathogenesis of articular cartilage
degradation during the development of OA7. Because NO
suppresses proteoglycan8 and collagen synthesis9, it is
thought to mediate some of the degradative effects of IL-1 on
cartilage. NO may be involved in the production and
activation of proteases and may modulate the production
of metalloproteinases10,11. This suggests that NO might
accelerate the proteolytic cleavage of aggrecan. In addition,
chondrocytes are known to produce large amounts of NO
when they are stimulated by proinﬂammatory cytokines12,
and the meniscus and synovium are also reported to
produce NO13,14.
The intraarticular injection of sodium hyaluronate (Na-HA)
has been extensively used in the treatment of OA in many
countries. Na-HA appears to be clinically effective as
indicated by a reduction in joint pain and improved joint
mobility15e17. Various studies on joint tissues18 and exper-
imental models of arthritis19,20 have examined effects of Na-
HA on cell function and tissue homeostasis. Na-HA has
a protective role against cartilage matrix degradation in
experimental OA21 and in cartilage explants treated with IL-1
or oxygen-derived free radicals22,23. It has been reported
that Na-HA stimulates the production of the tissue inhibitor
of metalloproteinase-1 (TIMP-1) from bovine articular
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Na-HA has also been shown to inhibit twomajor chondrolytic
activities of the ﬁbronectin fragment, the suppression of
synthesis of proteoglycan and the enhanced release of
stromelysin-1, both in vitro25 and in vivo26, although in
human cartilage Na-HA only delays MMP-3 induction by
a week and then the release of MMP-3 increases to non Na-
HA treated levels27. This in vitro study using human
cartilage27 also suggested that Na-HA enhances aggrecan
synthesis and reported that this effect was supported by
other researchers18,28,29. In addition, it has been demon-
strated that Na-HA has a suppressive effect on NO pro-
duction in the meniscus and synovium during development
of OA in animal models30,31.
Based on the results described above, it is speculated that
Na-HA may inhibit NO production from the synovium and
menisci and may also down-regulate the activity of pro-
teolytic factors, thus resulting in an increased level of intact
aggrecan in the knee joint cartilage of patients with OA. In
this study, the inhibitory effects of Na-HA on the release and
degradation of aggrecan were examined by measuring the
CS levels and the level of intact aggrecan in joint ﬂuid of
patients with knee OA. In addition, the effect of Na-HA on the
level of NO was also investigated. The relationship among
the parameters studied was further analyzed to clarify the
mechanism of Na-HA activity.
Materials and methods
PATIENT INCLUSION/EXCLUSION CRITERIA
Patients with OA were selected according to previously
described criteria17. Inclusion criteria were: idiopathic OA of
the knee as deﬁned by validated clinical and X-ray criteria
showing a sensitivity of 91% and a speciﬁcity of 86%32; an
age range of 50e70 years; and the informed consent of the
patient. All patient-related procedures were approved by the
Institutional Review Board of Inoue Memorial Hospital.
Exclusion criteria were: inﬂammatory joint diseases,
ESRO40mm after 1 h or RFO1:40, respectively; speciﬁc
arthropathies, for example, chondrocalcinosis; excessive
joint effusion (O40 ml); excessive obesity (Broca’s formula
+50%); severe axis deviations or instabilities; joint prosthesis
of the lower limbs; symptomatic OA of the hip ipsilateral to
the index knee; intraarticular injection, for example, the use
of corticosteroids within 3 months prior to testing; infectious
or febrile diseases; joint or skin infections; and pregnancy.
Patients were also required to abstain from other disallowed
medications, for example, other intraarticular injections,
corticosteroids, ‘chondroprotective’ agents, NSAIDs, and
analgesics other than occlusive dressings. Other estab-
lished treatments were allowed to continue unaltered during
the whole study period and were recorded.
PATIENT PROTOCOL/SAMPLE COLLECTION
Between April 2001 and February 2002, 16 patients (four
males and 12 females, mean age: 59.1 years) with knee OA
with joint effusion underwent 5 weekly intraarticular injec-
tions of Na-HA in the Department of Orthopaedics at the
Inoue Memorial Hospital. Diagnoses of OA were made
according to the criteria described above. These patients
were treated by 5 weekly intraarticular injections of 1% Na-
HA (800 kDa) solution, kindly provided by the Seikagaku
Corporation (Tokyo, Japan), with a dosage of 2.5 ml/
injection. On admission and before each Na-HA injection,
as much joint ﬂuid as possible was collected by usinga 19-gauge needle attached to a disposable injection
syringe. The joint ﬂuid specimens were transferred into
plastic tubes, centrifuged at 10 000g for 15 min to remove
cells and tissue debris and stored at 80(C until analyzed.
EFFICACY OF NA-HA: CLINICAL SYMPTOMS
The clinical efﬁcacy (clinical score) of Na-HA injected into
a knee joint with OA was studied by summing the scores for
joint pain and inﬂammatory parameters at the start of the
study (baseline) and at every weekly visit (assessment
score)33 for each patient. The clinical assessment of the OA
knee joint was always obtained prior to joint ﬂuid aspiration
and Na-HA injection. Brieﬂy, the degree of joint pain was
based on three different categories, pain at rest, pain in
motion and pain in passive motion, using a four-step rating
scale of 0Znone, 1Zmild, 2Zmoderate, and 3Zsevere.
The degree of joint inﬂammation was based on three
different categories, swelling, ﬂoating patella and local
warmth, using a four-step rating scale of 0Znone, 1Zmild,
2Zmoderate, and 3Zsevere. The improvement in both
degree of joint pain and joint inﬂammation was evaluated by
comparing the clinical scores at baseline with the assess-
ment score at weekly intervals for all patients.
The examination was performed blindly by two observers
and averaged to minimize observer bias. Because this is an
open label study, caution must be used in interpreting any
clinical data. The biochemical analyses described below
were performed separately from the clinical assessments.
The researchers analyzing each joint ﬂuid sample were
blinded to the results of the clinical assessment.
QUANTIFICATION OF CHONDROITIN 4- AND
CHONDROITIN 6-SULFATE
Chondroitin 4-sulfate (C4S) and chondroitin 6-sulfate
(C6S) levels in the joint ﬂuids were analyzed as previously
described34. The joint ﬂuids were ﬁrst treated by a series of
digestions with chondroitinase ABC and AC-II (Seikagaku
Corporation). The chondroitinase digestions produce the
unsaturated disaccharides, DDi-4S and DDi-6S from the
structure of C4S and C6S in CS chain. After ultraﬁltration of
the digested solutions, the levels of DDi-4S and DDi-6S in
the ﬁltrates were analyzed by high performance liquid
chromatography (HPLC).
DETERMINATION OF THE LEVEL OF INTACT AGGRECAN
For determining the amount of aggrecan in joint ﬂuid we
used an enzyme-linked immunosorbent assay (ELISA)
system based on the ability of intact aggrecan to bind to
HA. Micro-titer plates (96-well, Nalge Nunc International,
Tokyo, Japan) were coated with anti-KS antibody (5-D-4,
Seikagaku Corporation) dissolved in phosphate buffered
saline (PBS) at pH 7.4 at a concentration of 20 mg/ml and
incubated overnight at 4(C. The plates were washed twice
with PBS and then blocked (Immunoassay Stabilizer,
Advanced Biotechnologies Inc., Epsom, UK) for 2 h at room
temperature. The plates were then washed three times with
PBS containing 0.05% Tween-20 (Wako Pure Chemical
Industries, Osaka, Japan) (washing solution); this washing
procedure was used after each of the following steps. The
joint ﬂuid was diluted 10 or more times with PBS containing
1% bovine serum albumin (BSA, Seikagaku Corporation)
(dilution buffer). The series of standard solutions of intact
aggrecan was prepared by dissolving and diluting the intact
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(kindly provided by Seikagaku Corporation), by the dilution
buffer. The standard solutions and the diluted joint ﬂuids
were separately added to wells of the 5-D-4 coated micro-
titer plates and then incubated for 1 h at 37(C. Because
unbound 5-D-4 can bind with KS in the hyaluronan-binding
protein (HABP), in order to mask any excess, unbound 5-D-
4, a 1 mg/ml solution of keratan poly-sulfate (kindly provided
by Seikagaku Corporation) dissolved in the dilution buffer
was added to each well and the plates were incubated for 1 h
at 37(C. A solution of biotin-conjugated HABP (Seikagaku
Corporation) was added into each well at 0.3 mg/ml and the
plates were incubated for 1 h at 37(C. Then, a solution of
avidin-D conjugated with peroxidase (horseradish peroxi-
dase avidin-D, Funakoshi, Tokyo Japan), diluted 10 000
times with the dilution buffer, was added to each well and the
plates were incubated for 30 min at 37(C. A substrate
solution (TMB peroxidase substrate ELISA, Moss Inc.,
Pasadena, MD, USA) was then added to each well and the
plates were incubated for 15 min at 37(C. Finally, a solution
of 1 N HCl was added in order to stop the enzyme reaction,
and the absorbance of each well at 450 nm was measured
by a plate reader (Well reader SK601, Seikagaku Corpora-
tion). The concentration of intact aggrecan in each sample
that was able to bind to the HABP was determined using the
standard curve generated by the diluted standards. Each
specimen was analyzed in duplicate, and the obtained mean
value was reported as the result of an individual specimen.
The aggrecan, having its G1 domain (HA binding domain),
G2 domain and KS-rich region, can be detected by the
method described above. This aggrecan, namely aggrecan
aggregating with HA, was deﬁned as ‘‘intact aggrecan’’ in
this study.
QUANTIFICATION OF NITRITES
The NO level of the collected joint ﬂuids was estimated by
determining the total concentration of NO2 and NO3. The
joint ﬂuid was diluted with distilled water and then analyzed
by a ﬂow-injection system for NO2 and NO3 determination
(Tokyo Kasei Kogyo, Tokyo Japan). Brieﬂy, the diluted joint
ﬂuid sample was ﬁrst passed through a CdeCu reducing
column (Tokyo Kasei Kogyo). Under these conditions, NO2
in the sample is eluted as it is whereas NO3 is reduced to
NO2. The efﬂuent from the column was then mixed with
Griess reagent solution and then passed through a reaction
coil with a length of 10 m in a reaction oven setting at 40(C.
The Griess reagent reacts with NO2 and forms chrom-
ogens. The total concentration of NO2 and NO3 was
determined by a UV/VIS detector setting at 570 nm.
STATISTICAL ANALYSES
The results are expressed as the meanGS.E.M. of speci-
mens obtained from 14 to 16 patients. The statistical
analyses were performed using the paired two-tailed t test
comparing the values at baseline with each time point. A
correlation analysis was also performed among the clinical
scores and the joint ﬂuid levels of C4S, C6S, intact aggrecan
and NO.
Results
CLINICAL SCORE
The improvement in both degree of joint pain and joint
inﬂammation was evaluated by comparing the clinicalscores at baseline with the assessment score at weekly
intervals for all patients. Following 5 weekly intraarticular
injections of Na-HA into a knee joint with OA, a signiﬁcant
improvement in the clinical score for the degree of joint pain
and joint inﬂammation (baseline visit: 10:8G0:5; 5-week
visit: 6:8G0:8, P!0:001) was observed (Fig. 1). A
signiﬁcant reduction in the clinical score was recorded at
every evaluation point when compared to the baseline, pre-
treatment clinical score.
CS LEVELS
In this study, the measurement of the alteration of each
biochemical parameter was based on its concentration in the
original joint ﬂuid. The average volume of joint ﬂuid collected
decreased from 13 ml at baseline to 10 ml at the 5-week time
point, but this difference was not statistically signiﬁcant.
The levels of CS in the joint ﬂuids are represented by the
concentrations of the unsaturated disaccharides, DDi-4S
and DDi-6S, found after chondroitinase digestion. The con-
centrations of these disaccharides were both decreased by
the series of Na-HA injections, with signiﬁcant differences
observed at the 5-week time point (1 week after the ﬁnal
injection) (DDi-4S: 18G1 nmol=ml at baseline; 15G1 nmol=
ml at 5 weeks, P!0:05) [Fig. 2(A)] and (DDi-6S: 56G
6 nmol=ml at baseline to 41G4nmol=ml, at 5 weeks,
P!0:05) [Fig. 2(B)]).
INTACT AGGRECAN LEVELS
The joint ﬂuid level of intact aggrecan (aggregating with
HA) was stable during the series of Na-HA injections. The
Fig. 1. Efﬁcacy of Na-HA: clinical symptoms. The clinical efﬁcacy
(clinical score) of Na-HA injected into a knee joint with OA was
studied by summing the scores for pain and inﬂammatory
parameters at the start of the study (baseline) and at every weekly
visit (assessment score) for each patient. The clinical assessment
of the OA knee joint was always obtained prior to joint ﬂuid
aspiration and Na-HA injection. The results are presented as the
meanG S.E.M. of 16 patients. The P values were assessed by
comparing the scores from each weekly visit with the baseline
values. S.E.M.=standard error of the mean.
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the series of Na-HA injections until the 4-week time point,
after which it decreased slightly at the 5-week time point.
However, no statistically signiﬁcant differences were ob-
served at any time point (Fig. 3).
NO LEVELS
Although the deviation at each time point was large, the
average joint ﬂuid level of NO gradually decreased after the
Fig. 2. Joint ﬂuid levels of chondroitin 4-sulfate (C4S) and
chondroitin 6-sulfate (C6S). The levels of CS in the joint ﬂuids are
expressed as the concentrations of the unsaturated disaccharides,
C4S (DDi-4S) and C6S (DDi-6S) as determined by HPLC analysis
after chondroitinase digestion. (A) DDi-4S in the joint ﬂuid. (B) DDi-
6S in the joint ﬂuid; results expressed as the meansGS.E.M. of
14e16 patients. The P values were assessed by comparing the
levels at each weekly visit with the baseline levels. S.E.M.Zstandard
error of the mean.series of Na-HA injections and was signiﬁcantly decreased
1 week after the ﬁnal injection when compared with the
baseline level (NO: 100G16mM at baseline; 86G12mM at 5
weeks, P!0:05) (Fig. 4).
Fig. 3. Joint ﬂuid levels of intact aggrecan. The joint ﬂuid levels of
aggrecan that were able to bind to hyaluronan were measured by
an ELISA method. The results are presented as the meansGS.E.M.
of 13e15 patients. The P values were assessed by comparing the
levels at each weekly visit with the baseline levels. S.E.M.=standard
error of the mean.
Fig. 4. Joint ﬂuid levels of NO. The NO levels of the collected joint
ﬂuids were estimated by determining the total concentration of NO2

and NO3
. Concentrations of NO2 and NO3 were determined by the
ﬂow-injection analytical method described in the Materials and
methods. The results are presented as the meansGS.E.M. of 14e16
patients. The P values were assessed by comparing the levels at
each weekly visit with the baseline level. S.E.M.Zstandard error of
the mean.
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An analysis was performed to identify any correlations
among the study parameters: clinical score and joint ﬂuid
levels of C4S, C6S, intact aggrecan and NO (Table I). Not
surprisingly, a signiﬁcant correlation (P!0:001) was ob-
served between the joint ﬂuid levels of C4S and C6S. In
addition, a trend was identiﬁed for a positive correlation
(P!0:1) between the clinical score and both C4S and C6S
joint ﬂuid levels and for a negative correlation between the
joint ﬂuid levels of aggrecan and both C4S and C6S. No
signiﬁcant correlations between joint ﬂuid NO levels and the
other study parameters were identiﬁed.
Discussion
There are many reports that the intraarticular injection of
Na-HA is useful for the treatment of patients with knee
OA15e17. Consistent with these reports, we also found
signiﬁcant improvements in three clinical categories of both
joint pain and joint inﬂammation after the series of Na-HA
injections (Fig. 1), although caution must be exercised in the
interpretation of the clinical ﬁndings from this open label
study. Further, in this study, we attempted to clarify the
mechanism of Na-HA activity, using the joint ﬂuid obtained
immediately prior to the Na-HA injections for biochemical
analyses.
As shown in Fig. 2, the CS level in joint ﬂuid decreased
throughout the series of Na-HA injections, reaching signif-
icant levels of difference for both C4S and C6S 1 week after
the ﬁnal injection. Because CS, especially C6S, is a main
and relatively speciﬁc component of aggrecan in cartilage,
this result reﬂects the reduction of the total aggrecan level,
i.e., the sum of intact aggrecan and degraded aggrecan, in
the joint ﬂuid. It has been well established by other
researchers that the release of aggrecan from degenerated
cartilage was inhibited by Na-HA33,35; therefore, the results
shown in Fig. 2 indicate the inhibitory effect of Na-HA on
the release of aggrecan from the cartilage of patients with
knee OA.
On the other hand, even though the level of CS reﬂecting
total aggrecan was signiﬁcantly decreased, the level of intact
aggrecan, that was aggregating with HA, was stable during
the series of Na-HA injections (Fig. 3). This means the level
of degraded aggrecan alone was reduced in the joint ﬂuid by
the series of Na-HA injections. We interpret these results
shown in Figs. 2 and 3 indicate an inhibitory effect of Na-HA
on the release of aggrecan from the cartilage and also an up-
regulation by Na-HA of the intact aggrecan synthesis and/or
a down-regulation by Na-HA of intact aggrecan degradation
in the cartilage and in the joint ﬂuid. Both of these regulations
increase the amount of intact aggrecan in the cartilage, and
Table I
Correlation coefficients among study parameters: the clinical score
and joint fluid levels of C4S, C6S, intact aggrecan and NO
C4S C6S Intact aggrecan NO
Clinical
score
0.446
(P!0:1)
0.433
(P!0:1)
0.248 (NS) 0.239
(NS)
C4S 0.426 (P!0:1)
C6S 0.892
(P!0:001)
0.427 (P!0:1)
NO 0.052
(NS)
0.031
(NS)
0.076 (NS)
Number of patient: 15 or 16, NS: not signiﬁcant.must lead to an increase of intact aggrecan level in the joint
ﬂuid when the release rate of intact aggrecan is stable.
However, because the release rate of intact aggrecan was
reduced by Na-HA injection, the level of intact aggrecan did
not change signiﬁcantly in the joint ﬂuid. In other words, our
interpretation is that the decrease in level of released intact
aggrecan, which is induced by the inhibitory effect of Na-HA
on the release of aggrecan, is canceled by the increase in
level of released intact aggrecan, which is induced by the up-
regulation of the intact aggrecan synthesis and/or the down-
regulation of intact aggrecan degradation.
Some researchers have reported that Na-HA accelerated
aggrecan synthesis after it penetrated into degenerated
cartilage derived from human27,29, bovine18, and horse28.
This ﬁnding supports the possibility of the up-regulation by
Na-HA of the intact aggrecan synthesis in the cartilage of
patients treated in this study. In the other papers, Na-HA is
reported to (1) have a suppressive effect on the gene
expression of MMP-3 in the synovium during development of
OA in a rabbit model36, and to (2) stimulate the production of
TIMP-1 from bovine articular chondrocytes, thus, reducing
the stromelysin/TIMP-1 ratio24. These results suggest the
down-regulation by Na-HA of the intact aggrecan degrada-
tion in the cartilage and also in the joint ﬂuid. Therefore, we
consider that the results shown in Figs. 2 and 3 reﬂect the
complex effects of Na-HA, i.e., the inhibitory effect on
aggrecan release from the cartilage, the up-regulation of
intact aggrecan synthesis in the cartilage, and/or the down-
regulation of intact aggrecan degradation in the cartilage and
in the joint ﬂuid of patients with knee OA.
It is well known that NO has many physiological functions.
Several reports also implicate NO in the pathophysiology
of OA, including the elevation of nitrite levels in the joint
ﬂuids of patients with OA and rheumatoid arthritis37 and in
both the serum and joint ﬂuid of patients with OA37,38. A
recent study has shown elevated NO levels in the joint ﬂuid
from patients with temporomandibular disorders caused by
OA39. In addition, unlike chondrocytes recovered from
normal human articular cartilage, chondrocytes recovered
from patients with OA produce NO spontaneously40 and
express NO synthase41. Based on these ﬁndings, the
possibility exists that NO is involved in the proteolytic activity
in the joint tissues, upstream of the pathological process and
the symptoms of OA, such as joint inﬂammation. Because
recent studies on experimental OA induced by anterior
cruciate ligament transection or partial meniscectomy in
rabbits showed that Na-HA signiﬁcantly reduced NO
synthesis from the menisci and synovium30,31, we evaluated
the effect of Na-HA on NO levels in the joint ﬂuids of OA
patients. The present study demonstrates that the intra-
articular injection of Na-HA signiﬁcantly decreased the NO
level in the joint ﬂuid of the OA knee (Fig. 4). Therefore, we
conclude that Na-HA exerted its effect on joint ﬂuid NO levels
as a result of the down-regulation of NO production by the
menisci and/or synovium in the patient with OA.
The authors hypothesize that NO joint ﬂuid levels will be
linked with the degradation of aggrecan and also with the
symptoms of OA patients, as described above. Therefore,
we looked for any correlations among the joint ﬂuid levels of
NO, intact aggrecan and CS, and also with the clinical
score. However, contrary to our expectations, there were no
signiﬁcant correlations between joint ﬂuid NO levels and the
other parameters analyzed (Table 1). On the other hand,
there were tendencies (P!0:1) for positive correlations
between the clinical score and C4S or C6S levels. Thus, the
improvement of clinical symptoms by Na-HA is partially
based on the prevention of proteoglycan release from the
541Osteoarthritis and Cartilage Vol. 12, No. 7cartilage, whereas the level of NO in joint ﬂuid may be
reduced independently from the effects of Na-HA on the
prevention of aggrecan release or clinical symptoms.
In summary, the present study showed the possibility of a
suppressive effect on the release and degradation of
aggrecan and/or an accelerative effect on the synthesis of
aggrecan, as well as a suppressive effect on NO production
in the joint tissues of OA patients treated with a series of
Na-HA injections. This may be an important mechanism for
the activity of Na-HA during the development of OA. The
signiﬁcance and actual relationship of these two effects will
be important subjects in future studies.
References
1. Poole AR, Ionescu M, Swan A, Dieppe PA. Changes in
cartilage metabolism in arthritis are reﬂected by altered
serum and synovial ﬂuid levels of the cartilage pro-
teoglycan aggrecan. Implications for pathogenesis.
J Clin Invest 1994;94:25e33.
2. Roughley PJ, Mort JS. Ageing and the aggregating
proteoglycans of human articular cartilage. Clin Sci
1986;71:337e44.
3. Lohmander LS. The release of aggrecan fragments into
synovial ﬂuid after joint injury and in osteoarthritis.
J Rheumatol Suppl 1995;43:75e7.
4. Petersson IF, Sandqvist L, Svensson B, Saxne T.
Cartilage markers in synovial ﬂuid in symptomatic
knee osteoarthritis. Ann Rheum Dis 1997;56:64e7.
5. Messner K, Gillquist J, Bjornsson S, Lohmander LS.
Proteoglycan fragments in rabbit joint ﬂuid correla-
ted to arthrosis stage. Acta Orthop Scand 1993;64:
312e6.
6. Saxne T, Heinegard D. Synovial ﬂuid analysis of two
groups of proteoglycan epitopes distinguishes early
and late cartilage lesions. Arthritis Rheum 1992;35:
385e90.
7. Hashimoto S, Takahashi K, Amiel D, Coutts RD, Lotz
M. Chondrocyte apoptosis and nitric oxide production
during experimentally induced osteoarthritis. Arthritis
Rheum 1998;41:1266e74.
8. Taskiran D, Stefanovic-Racic M, Georgescu H, Evans
C. Nitric oxide mediates suppression of cartilage
proteoglycan synthesis by interleukin-1. Biochem
Biophys Res Commun 1994;200:142e8.
9. Cao M, Westerhausen-Larson A, Niyibizi C, Kavalko-
vich K, Georgescu HI, Rizzo CF, et al. Nitric oxide
inhibits the synthesis of type-II collagen without
altering Col2A1 mRNA abundance: prolyl hydroxylase
as a possible target. Biochem J 1997;324:305e10.
10. Murrell GA, Jang D, Williams RJ. Nitric oxide activates
metalloprotease enzymes in articular cartilage. Bio-
chem Biophys Res Commun 1995;206:15e21.
11. Sasaki K, Hattori T, Fujisawa T, Takahashi K, Inoue H,
Takigawa M. Nitric oxide mediates interleukin-1-in-
duced gene expression of matrix metalloproteinases
and basic ﬁbroblast growth factor in cultured rabbit
articular chondrocytes. J Biochem 1998;123:431e9.
12. Stadler J, Stefanovic-Racic M, Billiar TR, Curran RD,
McIntyre LA, Georgescu HI, et al. Articular chondro-
cytes synthesize nitric oxide in response to cytokines
and lipopolysaccharide. J Immunol 1991;147:
3915e20.
13. Cao M, Stefanovic-Racic M, Georgescu HI, Miller LA,
Evans CH. Generation of nitric oxide by lapine
meniscal cells and its effect on matrix metabolism:stimulation of collagen production by arginine. J Orthop
Res 1998;16:104e11.
14. Stefanovic-Racic M, Stadler J, Georgescu HI, Evans
CH. Nitric oxide synthesis and its regulation by rabbit
synoviocytes. J Rheumatol 1994;21:1892e8.
15. Jones AC, Pattrick M, Doherty S, Doherty M. Intra-
articular hyaluronic acid compared to intra-articular
triamcinolone hexacetonide in inﬂammatory knee
osteoarthritis. Osteoarthritis Cartilage 1995;3:269e73.
16. Lohmander LS, Dalen N, Englund G, Hamalainen M,
Jensen EM, Karlsson K, et al. Intra-articular hyalur-
onan injections in the treatment of osteoarthritis of
the knee: a randomised, double blind, placebo con-
trolled multicentre trial. Ann Rheum Dis 1996;55:
424e31.
17. Puhl W, Bernau A, Greiling H, Ko¨pcke W, Pfo¨rringer W,
Steck KJ, et al. Intra-articular sodium hyaluronate in
osteoarthritis of the knee: a multicenter, double-blind
study. Osteoarthritis Cartilage 1993;1:233e41.
18. Fukuda K, Dan H, Takayama M, Kumano F, Saitoh M,
Tanaka S. Hyaluronic acid increases proteoglycan
synthesis in bovine articular cartilage in the presence
of interleukin-1. J Pharmacol Exp Ther 1996;277:
1672e5.
19. Ghosh P, Read R, Armstrong S, Wilson D, Marshall R,
McNair P. The effects of intraarticular administration of
hyaluronan in amodel of early osteoarthritis in sheep. I.
Gait analysis and radiological and morphological
studies. Semin Arthritis Rheum 1993;22:18e30.
20. Yoshioka M, Shimizu C, Harwood FL, Coutts RD,
Amiel D. The effects of hyaluronan during the
development of osteoarthritis. Osteoarthritis Cartilage
1997;5:251e60.
21. Shimizu C, Yoshioka M, Coutts RD, Harwood FL, Kubo
T, Hirasawa Y, et al. Long-term effects of hyaluronan
on experimental osteoarthritis in the rabbit knee.
Osteoarthritis Cartilage 1998;6:1e9.
22. Shimazu A, Jikko A, Iwamoto M, Koike T, Yan W,
Okada Y, et al. Effects of hyaluronic acid on the
release of proteoglycan from the cell matrix in rabbit
chondrocyte cultures in the presence and absence of
cytokines. Arthritis Rheum 1993;36:247e53.
23. Cortivo R, Brun P, Cardarelli L, O’Regan M, Radice M,
Abatangelo G. Antioxidant effects of hyaluronan and
its alpha-methyl-prednisolone derivative in chondro-
cyte and cartilage cultures. Semin Arthritis Rheum
1996;26:492e501.
24. Yasui T, Akatsuka M, Tobetto K, Umemoto J, Ando T,
Yamashita K, et al. Effects of hyaluronan on the
production of stromelysin and tissue inhibitor of
metalloproteinase-1 (TIMP-1) in bovine articular chon-
drocytes. Biomed Res 1992;13:343e8.
25. Homandberg GA, Hui F, Wen C, Kuettner KE, Williams
JM. Hyaluronic acid suppresses ﬁbronectin fragment
mediated cartilage chondrolysis: I. In vitro. Osteoar-
thritis Cartilage 1997;5:309e19.
26. Williams JM, Plaza V, Hui F, Wen C, Kuettner KE,
Homandberg GA. Hyaluronic acid suppresses ﬁbro-
nectin fragment mediated cartilage chondrolysis: II.
In vivo. Osteoarthritis Cartilage 1997;5:235e40.
27. Kang Y, Eger W, Koepp H, Williams JM, Kuettner KE,
Homandberg GA. Hyaluronan suppresses ﬁbronectin
fragment-mediated damage to human cartilage ex-
plant cultures by enhancing proteoglycan synthesis.
J Orthop Res 1999;17:858e69.
28. Frean SP, Abraham LA, Lees P. In vitro stimulation of
equine articular cartilage proteoglycan synthesis by
542 K. Kobayashi et al.: Effects of hyaluronan on nitric oxide and aggrecanhyaluronan and carprofen. Res Vet Sci 1999;67:
183e90.
29. Sto¨ve J, Gerlach C, Huck K, Gunther KP, Puhl W,
Scharf HP. Effects of hyaluronan on proteoglycan
content of osteoarthritic chondrocytes in vitro.
J Orthop Res 2002;20:551e5.
30. Kobayashi K, Mishima H, Harwood F, Hashimoto S,
Toyoguchi T, Goomer R, et al. The suppressive
effect of hyaluronan on nitric oxide production and
cell apoptosis in the central region of meniscus fol-
lowing partial meniscectomy. Iowa Orthop J 2002;22:
39e41.
31. Takahashi K, Hashimoto S, Kubo T, Hirasawa Y, Lotz
M, Amiel D. Hyaluronan suppressed nitric oxide
production in the meniscus and synovium of rabbit
osteoarthritis model. J Orthop Res 2001;19:500e3.
32. Lequesne M, Wilhelm F. Validation of diagnostic criteria
and assessment or ‘new medical frontiers’ in the age
of the computer. In: Methodology for the Clinician.
Compendium and Glossary, Lequesne M, Wilhelm F,
Eds. Basel: Eular Publishers 1989;56e69.
33. Goto M, Hanyu T, Yoshio T, Matsuno H, Shimizu M,
Murata N, et al. Intra-articular injection of hyaluronate
(SI-6601D) improves joint pain and synovial ﬂuid pro-
staglandin E2 levels in rheumatoid arthritis: a multicen-
ter clinical trial. Clin Exp Rheumatol 2001;19:377e83.
34. Shinmei M, Miyauchi S, Machida A, Miyazaki K.
Quantitation of chondroitin 4-sulfate and chondroitin
6-sulfate in pathologic joint ﬂuid. Arthritis Rheum
1992;35:1304e8.
35. Kato Y, Mukudai Y, Okimura A, Shimazu A, Nakamura
S. Effects of hyaluronic acid on the release of cartilage
matrix proteoglycan and ﬁbronectin from the cell
matrix layer of chondrocyte cultures: interactions
between hyaluronic acid and chondroitin sulfateglycosaminoglycan. J Rheumatol Suppl 1995;43:
158e9.
36. Takahashi K, Goomer RS, Harwood F, Kubo T,
Hirasawa Y, Amiel D. The effects of hyaluronan on
matrix metalloproteinase-3 (MMP-3), interleukin-
1beta(IL-1beta), and tissue inhibitor of metalloprotei-
nase-1 (TIMP-1) gene expression during the
development of osteoarthritis. Osteoarthritis Cartilage
1999;7:182e90.
37. Farrell AJ, Blake DR, Palmer RM, Moncada S. In-
creased concentrations of nitrite in synovial ﬂuid and
serum samples suggest increased nitric oxide synthe-
sis in rheumatic diseases. Ann Rheum Dis 1992;51:
1219e22.
38. Renoux M, Hilliquin P, Galoppin L, Florentin I, Menkes
CJ. Release of mast cell mediators and nitrites into
knee joint ﬂuid in osteoarthritisdcomparison with
articular chondrocalcinosis and rheumatoid arthritis.
Osteoarthritis Cartilage 1996;4:175e9.
39. Takahashi T, Kondoh T, Kamei K, Seki H, Fukuda M,
Nagai H, et al. Elevated levels of nitric oxide in
synovial ﬂuid from patients with temporomandibular
disorders. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod 1996;82:505e9.
40. Amin AR, Attur M, Patel RN, Thakker GD, Marshall PJ,
Rediske J, et al. Superinduction of cyclooxygenase-2
activity in human osteoarthritis-affected cartilage.
Inﬂuence of nitric oxide. J Clin Invest 1997;99:
1231e7.
41. Amin AR, Di Cesare PE, Vyas P, Attur M, Tzeng E,
Billiar TR, et al. The expression and regulation of
nitric oxide synthase in human osteoarthritis-affected
chondrocytes: evidence for up-regulated neuronal
nitric oxide synthase. J Exp Med 1995;182:
2097e102.
